BR0213968A - Anticorpos humanos que apresentam ligação à proteìna superficial celular "mn" e atividade neutralizadora de aderência celular - Google Patents

Anticorpos humanos que apresentam ligação à proteìna superficial celular "mn" e atividade neutralizadora de aderência celular

Info

Publication number
BR0213968A
BR0213968A BR0213968-5A BR0213968A BR0213968A BR 0213968 A BR0213968 A BR 0213968A BR 0213968 A BR0213968 A BR 0213968A BR 0213968 A BR0213968 A BR 0213968A
Authority
BR
Brazil
Prior art keywords
antibodies
cell
human
binding
surface protein
Prior art date
Application number
BR0213968-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Toshihiko Takeuchi
Nathalie Dubois-Stringfellow
John E Murphy
Julie Rinkenberger
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BR0213968A publication Critical patent/BR0213968A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR0213968-5A 2001-10-18 2002-10-18 Anticorpos humanos que apresentam ligação à proteìna superficial celular "mn" e atividade neutralizadora de aderência celular BR0213968A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02
PCT/US2002/033470 WO2003033674A2 (en) 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity

Publications (1)

Publication Number Publication Date
BR0213968A true BR0213968A (pt) 2005-05-10

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213968-5A BR0213968A (pt) 2001-10-18 2002-10-18 Anticorpos humanos que apresentam ligação à proteìna superficial celular "mn" e atividade neutralizadora de aderência celular

Country Status (18)

Country Link
US (2) US7462696B2 (enExample)
EP (1) EP1438339A4 (enExample)
JP (2) JP2005528884A (enExample)
KR (1) KR20050037478A (enExample)
CN (1) CN1606569A (enExample)
AR (1) AR036833A1 (enExample)
BR (1) BR0213968A (enExample)
CA (1) CA2463943A1 (enExample)
CO (1) CO5370684A1 (enExample)
DO (1) DOP2002000494A (enExample)
HU (1) HUP0600335A2 (enExample)
IL (1) IL161411A0 (enExample)
MX (1) MXPA04003508A (enExample)
PE (1) PE20030473A1 (enExample)
PL (1) PL374304A1 (enExample)
RU (1) RU2317998C2 (enExample)
UY (1) UY27499A1 (enExample)
WO (1) WO2003033674A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7504365B2 (en) 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
EP4001920A1 (en) * 2014-04-03 2022-05-25 AllerGenis, LLC Peptides and methods for detecting food allergy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
WO1995034650A2 (en) * 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
AU758957C (en) * 1998-10-23 2004-08-12 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
PE20030473A1 (es) 2003-06-26
CO5370684A1 (es) 2004-02-27
MXPA04003508A (es) 2004-07-22
UY27499A1 (es) 2003-05-30
RU2317998C2 (ru) 2008-02-27
WO2003033674A3 (en) 2003-08-21
CA2463943A1 (en) 2003-04-24
US20100240100A1 (en) 2010-09-23
DOP2002000494A (es) 2004-05-31
AR036833A1 (es) 2004-10-06
PL374304A1 (en) 2005-10-03
IL161411A0 (en) 2004-09-27
JP2010260845A (ja) 2010-11-18
KR20050037478A (ko) 2005-04-22
US7462696B2 (en) 2008-12-09
WO2003033674A2 (en) 2003-04-24
CN1606569A (zh) 2005-04-13
EP1438339A2 (en) 2004-07-21
HUP0600335A2 (en) 2006-08-28
US20030077277A1 (en) 2003-04-24
JP2005528884A (ja) 2005-09-29
EP1438339A4 (en) 2008-08-27
RU2004115112A (ru) 2005-04-27

Similar Documents

Publication Publication Date Title
WO2003033674A3 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
Elefteriou et al. Binding of tenascin‐X to decorin
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
CN106699891B (zh) 一种抗pd-l1抗体、其药物组合物及其用途
BR0311799A (pt) Anticorpo monoclonal hpam4
AR108005A1 (es) Anticuerpos, composiciones y métodos farmacéuticos
ES2765423T3 (es) Sistemas y procedimientos de anticuerpos anti-SOX10
BR112013001640A2 (pt) anticorpo monoclonal que se liga aos epítopos de epha2 e cd44, seu uso no tratamento de câncer e na detecção de célula cancerosa, bem como composição, kit, ácido nucleico e vetor 5 de expressão
BR0315117A (pt) Anticorpos anti-erb-b biespecìficos e seu uso na terapia de tumores
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
EP2287201A3 (en) RS7 antibodies
De Lorenzo et al. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
CN103483450A (zh) 抗人cxcl1单克隆抗体或其片段
ATE173740T1 (de) Antikoerper mit geaenderter zielrichtung
RU2017138468A (ru) Антитела против человеческого her3, имеющие низкое содержание фукозы, и области их применения
KR20160114088A (ko) 진단을 위한 세포 표면 전립선암 항원
CN119060188B (zh) 抗人基质金属蛋白酶9抗体、抗体对和检测试剂盒
JP2008519841A5 (enExample)
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
BRPI0411945A (pt) Anticorpos e seus usos
KR900013987A (ko) 망막아종 유전자 생성물에 대한 항체 및 이의 용도
Tiniakos et al. Studies of c‐jun oncogene expression in human breast using a new monoclonal antibody, NCL‐DK4
Mukaratirwa et al. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.